This current report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among other things, those relating to: the expected conclusion of the offer and the expected product of the offer. Words anticipate, believe, could continue, estimate, wait, plan, can, can, plan, possible, potentially, project, project, would, identify, and similar expressions are supposed to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are subject to a number of significant factors, risks and uncertainties that may result in actual events or results differing materially from current expectations and beliefs, including, but not limited to,: risks and uncertainties related to the satisfaction of normal supply completion conditions; Uncertainties related to general and sectoral market conditions; the current and future effects of the ongoing COVID 19 pandemic on the entity`s commercial, financial, commercial and liquidity activities; The company`s ability to advance the development of its platform and programs on schedule, demonstrate the necessary safety and effectiveness of its candidates, and replicate all positive results from preclinical studies in clinical trials; The successful development of the cooperation agreement between the company and Sanofi; Uncertainties regarding the discovery and development of mNSA-based vaccines, particularly with respect to COVID-19; The content and date of decisions by the U.S. Food and Drug Administration, other supervisory authorities and audit committees at clinical trial sites, including decisions on ongoing and planned clinical trials; The company`s ability to obtain, preserve and enforce patent rights and other intellectual property protections; The availability of significant funds needed to finance operations; Competitiveness factors the impact of general economic, industrial or political conditions in the U.S. or internationally and other important risk factors discussed in the risk factors section of the preliminary prospectus regarding the offer submitted to the SEC on June 24, 2020, in the Company`s Quarterly Report on Form 10-Q for the quarterly period of March 7, 2020 , 2020 and in all subsequent notifications that has been filed by the company with the SEC. All forward-looking statements contained in this report on Form 8-K refer only to the date of this page, and the Company expressly denies any obligation to update any forward-looking statements, whether on the basis of new information, future events or otherwise. (j) Neither the company`s performance and provision of the obligations arising from this agreement, neither the issuance and sale of the shares by the company, nor the issuance and sale of the shares, contras a provision of the applicable law (ii) of the incorporation or statutes of the company, (iii) of an agreement or other instrument binding the company or one of its subsidiaries which is essential to the company and its subsidiaries and which is essential to The company and its subsidiaries. ( iv) any judgment, order or decree of a public authority, agency or court responsible for the company or subsidiary, with the exception of clauses i, iii) and (iv), as would not be the case individually or as a whole, to reasonably expect a material adverse impact on the company and its subsidiaries as a whole, or on the power and ability of the company to fulfil its obligations under this agreement.